Modeling and predicting clinical efficacy for drugs targeting the tumor milieu

Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway

(2012) Vesselina G. Cooke et al.   CANCER CELL

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

(2012) Zhao Chen et al.   NATURE

Raise standards for preclinical cancer research

(2012) C. Glenn Begley et al.   NATURE

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

Unraveling the Genetics of Cancer: Genome Sequencing and Beyond

(2011) Kit Man Wong et al.   Annual Review of Genomics and Human Genetics

Lung Cancer Signatures in Plasma Based on Proteome Profiling of Mouse Tumor Models

(2011) Ayumu Taguchi et al.   CANCER CELL

Chemotherapeutic Resistance: Surviving Stressful Situations

(2011) L. A. Gilbert et al.   CANCER RESEARCH

A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference

(2011) Prem K. Premsrirut et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics

(2011) H. I. Scher et al.   CLINICAL CANCER RESEARCH

Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition

(2011) Elizabeth Allen et al.   CLINICAL CANCER RESEARCH

Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

(2011) H. Wong et al.   CLINICAL CANCER RESEARCH

Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?

(2011) David Bruce et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?

(2011) Yihai Cao   INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY

Randomized Phase II Trials: A Long-term Investment With Promising Returns

(2011) M. R. Sharma et al.   JNCI-Journal of the National Cancer Institute

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

(2011) Hedy L Kindler et al.   LANCET ONCOLOGY

Translational research: The American way

(2011) Amy Maxmen   NATURE

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer

(2011) Samir M. Hanash et al.   Nature Reviews Clinical Oncology

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Cancer immunotherapy – revisited

(2011) W. Joost Lesterhuis et al.   NATURE REVIEWS DRUG DISCOVERY

Towards systematic functional characterization of cancer genomes

(2011) Jesse S. Boehm et al.   NATURE REVIEWS GENETICS

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

(2011) Timothy J. Perren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma

(2011) P. Olson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Accrual to Cancer Clinical Trials in the Era of Molecular Medicine

(2011) R. L. Schilsky   Science Translational Medicine

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Prediction of Exposure–Response Relationships to Support First-in-Human Study Design

(2010) John P. Gibbs   AAPS Journal

Antiangiogenic agents and targets: A perspective

(2010) Beverly A. Teicher   BIOCHEMICAL PHARMACOLOGY

Guidelines for the welfare and use of animals in cancer research

(2010) P Workman et al.   BRITISH JOURNAL OF CANCER

FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis

(2010) Pauline Andreu et al.   CANCER CELL

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner

(2010) Neta Erez et al.   CANCER CELL

DNA Damage-Mediated Induction of a Chemoresistant Niche

(2010) Luke A. Gilbert et al.   CELL

Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed in the Right Direction?

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies

(2010) N. A. de Vries et al.   CLINICAL CANCER RESEARCH

Hallmarks of cancer: Interactions with the tumor stroma

(2010) Kristian Pietras et al.   EXPERIMENTAL CELL RESEARCH

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

(2010) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor-Host Interactions: A Far-Reaching Relationship

(2010) Sandra S. McAllister et al.   JOURNAL OF CLINICAL ONCOLOGY

Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials

(2010) David Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

(2010) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Towards patient-based cancer therapeutics

(2010) Stuart L Schreiber et al.   NATURE BIOTECHNOLOGY

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

(2010) Mallika Singh et al.   NATURE BIOTECHNOLOGY

Finding the tumor copycat: Approximating a human cancer

(2010) Terry Van Dyke   NATURE MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy

(2010) Axel Hoos et al.   SEMINARS IN ONCOLOGY

Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade

(2010) Jeffrey Weber   SEMINARS IN ONCOLOGY

Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy

(2010) Margaret K. Callahan et al.   SEMINARS IN ONCOLOGY

Predictive Toxicology Approaches for Small Molecule Oncology Drugs

(2010) T. Maziasz et al.   TOXICOLOGIC PATHOLOGY

PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

(2009) Yongping Crawford et al.   CANCER CELL

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

(2009) Marta Pàez-Ribes et al.   CANCER CELL

Sunitinib Prolongs Survival in Genetically Engineered Mouse Models of Multistep Lung Carcinogenesis

(2009) L. Gandhi et al.   Cancer Prevention Research

Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer

(2009) M. Pajic et al.   CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

(2009) K. Politi et al.   Disease Models & Mechanisms

The use of endostatin in the treatment of solid tumors

(2009) Michalis V Karamouzis et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cancer associated fibroblasts (CAFs) in tumor microenvironment

(2009) Fei Xing   Frontiers in Bioscience-Landmark

Mouse models of human AML accurately predict chemotherapy response

(2009) J. Zuber et al.   GENES & DEVELOPMENT

Matrix Metalloproteinases As Novel Biomarker s and Potential Therapeutic Targets in Human Cancer

(2009) Roopali Roy et al.   JOURNAL OF CLINICAL ONCOLOGY

Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development

(2009) Sean Ekins et al.   LAB ON A CHIP

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas

(2009) Yinghui Zhou et al.   NATURE BIOTECHNOLOGY

Mechanisms of drug combinations: interaction and network perspectives

(2009) Jia Jia et al.   NATURE REVIEWS DRUG DISCOVERY

Cell-type-specific isolation of ribosome-associated mRNA from complex tissues

(2009) E. Sanz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

(2009) Yongping Crawford et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Application of a Translational Profiling Approach for the Comparative Analysis of CNS Cell Types

(2008) Joseph P. Doyle et al.   CELL

A Translational Profiling Approach for the Molecular Characterization of CNS Cell Types

(2008) Myriam Heiman et al.   CELL

Modeling therapy resistance in genetically engineered mouse cancer models

(2008) S ROTTENBERG et al.   DRUG RESISTANCE UPDATES

Cancer and Immune Response: Old and New Evidence for Future Challenges

(2008) L. de la Cruz-Merino et al.   ONCOLOGIST

In Vivo/Ex Vivo and In Situ Assays Used in Cancer Research: A Brief Review

(2008) Beverly A. Teicher   TOXICOLOGIC PATHOLOGY

Development trends for new cancer therapeutics and vaccines

(2007) J REICHERT   DRUG DISCOVERY TODAY